Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 228 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular Disease Other Clear all
Completed No phase listed Observational

Follow-Up Study of People Treated for Scoliosis

NCT02546479
View directory record Official record
Conditions
Breast and Other Cancer Incidence and Mortality, All Cause Mortality, Circulatory Disease Mortality, Respiratory Disease Mortality
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 95 Years · Female only
Enrollment
5,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
100
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Prenatal Diagnostic Validation Study

NCT01574781
View directory record Official record
Conditions
Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations, Other Microdeletions
Interventions
Blood draw, Cheek swab/Saliva Sampling
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,781 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 8, 2026, 5:37 AM EDT
Withdrawn Early Phase 1 Interventional

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease

NCT04346394
View directory record Official record
Conditions
Parkinson Disease
Interventions
Yohimbine HCl
Drug
Lead sponsor
Nathaniel M. Robbins
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 8, 2026, 5:37 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292
View directory record Official record
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 8, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

NCT04439253
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Crizotinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 8, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

NCT00719849
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

NCT02993614
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional

The IMPULSE Study: Pilot

NCT02044471
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Remote Ischemic Conditioning (using Sphygmomanometer)
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic

NCT02679599
View directory record Official record
Conditions
Acute Coronary Syndrome, Heart Failure, Other Cardiac Conditions Among Cardiac Rehabilitation Participants
Interventions
B-MOBILE-CARDIAC smartphone application, Cardiac rehabilitation as usual
Other · Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

NCT04439344
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Binimetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT07284641
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions
Hematopoietic stem cell transplant (HSCT)
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery

NCT04481737
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity, Cardiovascular Diseases, Diabetes, Smoking, Blood Pressure Disorders, Cholesterol, Elevated
Interventions
Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities

NCT00767923
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Not listed
Lead sponsor
HyperMed
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 8, 2026, 5:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients

NCT00501163
View directory record Official record
Conditions
Schizophrenia, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

NCT00357084
View directory record Official record
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 8, 2026, 5:37 AM EDT